Lipocine (LPCN) Short term Debt (2018 - 2022)
Lipocine's (LPCN) quarterly Short term Debt came in at $1.5 million in Q1 2022, down 55.54% YoY from $3.3 million in Q1 2021, and down 35.86% on a QoQ basis from $2.3 million in Q4 2021.
Lipocine (LPCN) Short term Debt (2018 - 2022) Analysis & Trends
Lipocine (LPCN) has 5 years of Short term Debt data on file, last reported at $1.5 million in Q1 2022.
- Quarterly Short term Debt fell 55.54% year-over-year to $1.5 million in Q1 2022, while the trailing twelve-month figure through Mar 2022 was $1.5 million (down 55.54% YoY) and the FY2021 annual result came in at $2.3 million, down 30.68% from the prior year.
- Short term Debt declined to $1.5 million in Q1 2022, from $2.3 million in the prior quarter.
- In the past five years, Short term Debt ranged from a high of $4.0 million in Q2 2021 to a low of $1.3 million in Q1 2018.
- A 5-year average of $2.7 million and a median of $3.2 million in 2020 frame the typical range for Short term Debt.
- Annual changes were most pronounced in 2019 — Short term Debt jumped 148.66% — and 2022, when it plunged 55.54%.
- Tracing LPCN's Short term Debt over 5 years: stood at $3.3 million in 2018, then changed by 0.0% to $3.3 million in 2019, then changed by 0.0% to $3.3 million in 2020, then plunged by 30.68% to $2.3 million in 2021, then tumbled by 35.86% to $1.5 million in 2022.
- The last three Short term Debt figures came in at $1.5 million (Q1 2022), $2.3 million (Q4 2021), and $3.1 million (Q3 2021), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Lipocine | 11.15 Mn | -12.76 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 1.48 Mn |
| Dec 31, 2021 | 2.31 Mn |
| Sep 30, 2021 | 3.14 Mn |
| Jun 30, 2021 | 3.96 Mn |
| Mar 31, 2021 | 3.33 Mn |
| Dec 31, 2020 | 3.33 Mn |
| Sep 30, 2020 | 3.21 Mn |
| Jun 30, 2020 | 2.33 Mn |
| Mar 31, 2020 | 1.67 Mn |
| Dec 31, 2019 | 3.33 Mn |
| Sep 30, 2019 | 3.33 Mn |
| Jun 30, 2019 | 3.33 Mn |
| Mar 31, 2019 | 3.33 Mn |
| Dec 31, 2018 | 3.33 Mn |
| Sep 30, 2018 | 2.34 Mn |
| Jun 30, 2018 | 1.55 Mn |
| Mar 31, 2018 | 1.34 Mn |